Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 177

Sort by

Sort Order Select

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood (2025) 146 (25): 3050–3058.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load

Blood blood.2025030083.

https://doi.org/10.1182/blood.2025030083

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2025-2288

Published: 2025

Journal Articles

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Julie Castiaux, Noemie Bigot, Cyrille Hulin, Magaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Aurore Perrot, Jean-Yves Mary, Jill Corre, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon, Jerome Lambert, Salomon Manier

Blood (2025) 146 (Supplement 1): 498.

https://doi.org/10.1182/blood-2025-498

Published: 2025

Journal Articles

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 497.

https://doi.org/10.1182/blood-2025-497

Published: 2025

Journal Articles

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Blood (2025) 146 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2025-5836

Published: 2025

Journal Articles

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Blood (2025) 146 (Supplement 1): 101.

https://doi.org/10.1182/blood-2025-101

Published: 2025

Journal Articles

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Blood (2025) 146 (Supplement 1): 744.

https://doi.org/10.1182/blood-2025-744

Published: 2025

Journal Articles

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Blood (2025) 146 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2025-2282

Published: 2025

Journal Articles

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Blood (2025) 146 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2025-2275

Published: 2025

Journal Articles

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 368.

https://doi.org/10.1182/blood-2025-368

Published: 2025

Journal Articles

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Blood (2025) 146 (Supplement 1): 367.

https://doi.org/10.1182/blood-2025-367

Published: 2025

Journal Articles

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Blood (2025) 146 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2025-4076

Published: 2025

Journal Articles

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Blood (2025) 146 (6): 679–692.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mourad Tiab, Mohamad Mohty, Frederique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini-Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hebraud, Laurent Flet, Jean-Valere Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cecile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Helene Demarquette, Valentine Richez, Brieuc Cherel, Laurent Frenzel, Marie-Christiane Vekemans, Noemie Bigot, Herve Avet-Loiseau, Jill Corre, Philippe Moreau

Blood (2025) 146 (1): 52–61.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again

Jules Higué, Gaetan Basile, Titouan Cazaubiel, Anne Banos, Guillaume Beziat, Martin Gauthier, Miguel Carreiro, Noemie Gadaud, Benjamin Hebraud, Miguel Granell, Pierre Bories, Christian Récher, Jill Corre, Cyrille Hulin, Aurore Perrot, Leopoldine Lapierre, Pierre Luc Mouchel

Blood (2024) 144 (Supplement 1): 7030.

https://doi.org/10.1182/blood-2024-206954

Published: 2024

Journal Articles

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 774.

https://doi.org/10.1182/blood-2024-203045

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar

Blood (2024) 144 (Supplement 1): 1975.

https://doi.org/10.1182/blood-2024-199773

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only